import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "hexarelin-cd36-cardiac-research-deep-dive",
  title: "Hexarelin and CD36: The Cardiac Research Deep Dive",
  description:
    "A thorough research overview of Hexarelin — a synthetic hexapeptide studied for potent GH secretagogue activity and cardioprotective effects mediated via the CD36 receptor pathway, independent of GH elevation.",
  category: "Compound Profiles",
  readMinutes: 9,
  publishedAt: "2026-06-05",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Hexarelin (sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide and potent growth hormone secretagogue (GHS) developed in the early 1990s. It acts as an agonist at the GHS-R1a receptor (ghrelin receptor) and has been studied extensively for GH-releasing effects, hypothalamic-pituitary axis interactions, and — notably — a range of cardioprotective properties that appear to be at least partially independent of GH secretion.",
    },
    {
      type: "paragraph",
      text: "This latter finding has made Hexarelin one of the more scientifically interesting research peptides in cardiovascular pre-clinical research and a valuable pharmacological probe for CD36 receptor function.",
    },
    {
      type: "heading",
      text: "Mechanism of Action",
    },
    {
      type: "subheading",
      text: "GHS-R1a Agonism",
    },
    {
      type: "paragraph",
      text: "Like other GHS compounds (Ipamorelin, GHRP-6, MK-677), Hexarelin binds to and activates the GHS-R1a receptor expressed in the pituitary, hypothalamus, and peripheral tissues. GHS-R1a activation in the pituitary triggers GH release; in peripheral tissues, it mediates several non-GH effects.",
    },
    {
      type: "paragraph",
      text: "Hexarelin is among the most potent GHS compounds studied, producing substantial GH release at relatively low concentrations in pre-clinical models. However, unlike some GHSs, Hexarelin shows significant desensitization with continuous administration — a relevant consideration for research protocol design.",
    },
    {
      type: "subheading",
      text: "CD36 Receptor Binding",
    },
    {
      type: "paragraph",
      text: "A critical and distinguishing feature of Hexarelin research is its interaction with CD36 — a scavenger receptor expressed on cardiac myocytes, endothelial cells, and macrophages. CD36 has multiple roles including fatty acid uptake and utilization in cardiac tissue, oxidized LDL recognition relevant to atherosclerosis, and angiogenesis regulation.",
    },
    {
      type: "paragraph",
      text: "Hexarelin's binding to CD36 in cardiac tissue is thought to mediate its cardioprotective effects independently of GH or IGF-1 elevation. This was established in GH-deficient animal models where cardioprotective effects persisted despite negligible GH response.",
    },
    {
      type: "heading",
      text: "Growth Hormone Research Data",
    },
    {
      type: "subheading",
      text: "Comparison to Other GHSs",
    },
    {
      type: "list",
      items: [
        "Hexarelin produces greater peak GH secretion than GHRP-6 and Ipamorelin in most rodent models",
        "This potency advantage is partially offset by rapid desensitization — repeated administration leads to blunted GH response more rapidly than with Ipamorelin",
        "Co-administration with GHRH analogs produces synergistic GH release, documented across multiple GHS compounds",
      ],
    },
    {
      type: "subheading",
      text: "Cortisol and Prolactin",
    },
    {
      type: "paragraph",
      text: "Unlike Ipamorelin, Hexarelin is not selective for GH at higher doses — it stimulates cortisol and prolactin secretion in a dose-dependent manner. This is an important consideration for research protocols where hormonal specificity is required.",
    },
    {
      type: "heading",
      text: "Cardioprotective Research",
    },
    {
      type: "paragraph",
      text: "The cardioprotective profile of Hexarelin is the most distinctive aspect of its research history and the area with the strongest mechanistic characterization.",
    },
    {
      type: "subheading",
      text: "Ischemia-Reperfusion Injury",
    },
    {
      type: "paragraph",
      text: "Studies in isolated heart preparations and in vivo rodent models have documented that Hexarelin reduces ischemia-reperfusion (I/R) injury — the cell death and dysfunction that occurs when blood flow is restored after a period of ischemia. Locatelli et al. (1999) and subsequent work demonstrated that Hexarelin pre-treatment in rats reduced infarct size following coronary occlusion/reperfusion.",
    },
    {
      type: "list",
      items: [
        "Effects were present in hypophysectomized (GH-deficient) animals — confirming the mechanism is not GH-dependent",
        "Effects were blocked by CD36 antagonism — confirming CD36 as the relevant mediator in cardiac tissue",
        "Protection was dose-dependent within the studied concentration range",
      ],
    },
    {
      type: "subheading",
      text: "Cardiac Function in GH Deficiency",
    },
    {
      type: "paragraph",
      text: "GH-deficient patients and animal models consistently show impaired cardiac function — reduced cardiac output, increased vascular resistance, and altered cardiac morphology. Hexarelin treatment in GH-deficient models has shown improved cardiac output and ejection fraction, reduction in left ventricular hypertrophy in some models, and improved ventricular contractility in isolated heart preparations.",
    },
    {
      type: "subheading",
      text: "Anti-Apoptotic Effects",
    },
    {
      type: "paragraph",
      text: "Hexarelin treatment in cardiac research models has been associated with reduced cardiomyocyte apoptosis following ischemic stress, upregulation of anti-apoptotic proteins (Bcl-2 family), and reduced cytochrome c release from mitochondria — suggesting cardioprotection at the mitochondrial level.",
    },
    {
      type: "heading",
      text: "The CD36 Pathway as a Research Focus",
    },
    {
      type: "paragraph",
      text: "The identification of CD36 as a Hexarelin receptor in cardiac tissue opened a new dimension of GHS research. CD36 had been primarily studied in the context of lipid metabolism and atherosclerosis, but Hexarelin research has implicated it in cardioprotection signaling, anti-inflammatory effects in vascular tissue, and potential relevance to metabolic syndrome research where CD36 is involved in fatty acid uptake dysregulation in obesity.",
    },
    {
      type: "callout",
      text: "This makes Hexarelin not only a GHS research tool but also a pharmacological probe for CD36 function — a use case of independent scientific value separate from its GH-releasing properties.",
    },
    {
      type: "heading",
      text: "Research Protocol Considerations",
    },
    {
      type: "table",
      headers: ["Parameter", "Notes"],
      rows: [
        ["Solubility", "Water-soluble; reconstitute in bacteriostatic water"],
        ["Stability in solution", "Store at 2–8°C after reconstitution; use within 4 weeks"],
        ["Desensitization", "Significant with continuous administration; intermittent protocols recommended"],
        ["GH selectivity", "Less selective than Ipamorelin; cortisol and prolactin co-stimulated at higher doses"],
        ["Purity requirement", "HPLC ≥98%; mass spec identity confirmation essential"],
        ["Model relevance", "GH-deficient models isolate CD36-mediated cardiac effects from GH-dependent effects"],
      ],
    },
    {
      type: "heading",
      text: "Summary",
    },
    {
      type: "paragraph",
      text: "Hexarelin occupies a unique position in GHS research: it is among the most potent GH-releasing peptides studied, while simultaneously demonstrating cardioprotective effects through a GH-independent CD36-mediated pathway. The ischemia-reperfusion protection data is well-replicated in animal models, and the CD36 mechanism is mechanistically characterized with antagonism studies. Its lower GH selectivity compared to Ipamorelin and its rapid desensitization profile are relevant practical considerations for research design.",
    },
    {
      type: "disclaimer",
      text: "All Nexphoria compounds are sold exclusively for qualified research use. They are not intended for human consumption, therapeutic use, or diagnostic purposes. Nothing on this site constitutes medical advice.",
    },
  ],
};
